The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma

Pigment Cell and Melanoma Research

Volumn 24, Issue 4, 2011, Pages 714-723

  Liang, Ruixia ^a   Wallace, Andrea R ^a   Schadendorf, Dirk ^b   Rubin, Brian P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Animal; In vitro cancer model; Kit; Melanoma; Receptor tyrosine kinase; Signal transduction; Small molecule tyrosine kinase inhibitor

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; ONCOGENE C KIT; PATHOGENESIS; PHENOTYPE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; HUMANS; MELANOCYTES; MELANOMA; MICE; MODELS, BIOLOGICAL; MUTANT PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; THIAZOLES;

ANIMALIA;

EID: 80051892946     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00870.x     Document Type: Article

References (37)

1. Alexeev, V., and Yoon, K. (2006). Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J. Invest. Dermatol. 126, 1102-1110.
2. Antonescu, C.R., Busam, K.J., Francone, T.D. et al. (2007). L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int. J. Cancer 121, 257-264.
3. Ashida, A., Takata, M., Murata, H., Kido, K., and Saida, T. (2009). Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int. J. Cancer 124, 862-868.
4. Beadling, C., Jacobson-Dunlop, E., Hodi, F.S. et al. (2008). KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14, 6821-6828.
5. Blanke, C.D., Demetri, G.D., Von Mehren, M. et al. (2008). Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26, 620-625.
6. Chin, L., Garraway, L.A., and Fisher, D.E. (2006). Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 20, 2149-2182.
7. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
8. Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346.
9. Dickins, R.A., Hemann, M.T., Zilfou, J.T., Simpson, D.R., Ibarra, I., Hannon, G.J., and Lowe, S.W. (2005). Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37, 1289-1295.
10. Fecher, L.A., Cummings, S.D., Keefe, M.J., and Alani, R.M. (2007). Toward a molecular classification of melanoma. J. Clin. Oncol. 25, 1606-1620.
11. Furitsu, T., Tsujimura, T., Tono, T. et al. (1993). Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92, 1736-1744.
12. Gajiwala, K.S., Wu, J.C., Christensen, J. et al. (2009). KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl. Acad. Sci. U S A 106, 1542-1547.
13. Ha, L., Ichikawa, T., Anver, M. et al. (2007). ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc. Natl. Acad. Sci. U S A 104, 10968-10973.
14. Hall, A.M., and Orlow, S.J. (2005). Degradation of tyrosinase induced by phenylthiourea occurs following Golgi maturation. Pigment Cell Res. 18, 122-129.
15. Heinrich, M.C., Corless, C.L., Blanke, C.D. et al. (2006). Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 24, 4764-4774.
16. Heinrich, M.C., Joensuu, H., Demetri, G.D. et al. (2008a). Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin. Cancer Res. 14, 2717-2725.
17. Heinrich, M.C., Owzar, K., Corless, C.L. et al. (2008b). Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J. Clin. Oncol. 26, 5360-5367.
18. Hirota, S., Isozaki, K., Moriyama, Y. et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580.
19. Hodi, F.S., Friedlander, P., Corless, C.L. et al. (2008). Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26, 2046-2051.
20. Houghton, A.N., and Polsky, D. (2002). Focus on melanoma. Cancer Cell 2, 275-278.
21. Jiang, X., Zhou, J., Yuen, N.K., Corless, C.L., Heinrich, M.C., Fletcher, J.A., Demetri, G.D., Widlund, H.R., Fisher, D.E., and Hodi, F.S. (2008). Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin. Cancer Res. 14, 7726-7732.
22. Kim, K.B., Eton, O., Davis, D.W. et al. (2008). Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br. J. Cancer 99, 734-740.
23. Lutzky, J., Bauer, J., and Bastian, B.C. (2008). Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 21, 492-493.
24. Monsel, G., Ortonne, N., Bagot, M., Bensussan, A., and Dumaz, N. (2010). c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 29, 227-236.
25. Oancea, E., Vriens, J., Brauchi, S., Jun, J., Splawski, I., and Clapham, D.E. (2009). TRPM1 forms ion channels associated with melanin content in melanocytes. Sci. Signal. 2, ra21.
26. Rivera, R.S., Nagatsuka, H., Gunduz, M., Cengiz, B., Gunduz, E., Siar, C.H., Tsujigiwa, H., Tamamura, R., Han, K.N., and Nagai, N. (2008). C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch. 452, 27-32.
27. Rubin, B.P., Heinrich, M.C., and Corless, C.L. (2007). Gastrointestinal stromal tumour. Lancet 369, 1731-1741.
28. Satzger, I., Schaefer, T., Kuettler, U., Broecker, V., Voelker, B., Ostertag, H., Kapp, A., and Gutzmer, R. (2008). Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br. J. Cancer 99, 2065-2069.
29. Serve, H., Hsu, Y.C., and Besmer, P. (1994). Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J. Biol. Chem. 269, 6026-6030.
30. Sviderskaya, E.V., Hill, S.P., Evans-Whipp, T.J., Chin, L., Orlow, S.J., Easty, D.J., Cheong, S.C., Beach, D., Depinho, R.A., and Bennett, D.C. (2002). p16(Ink4a) in melanocyte senescence and differentiation. J. Natl Cancer Inst. 94, 446-454.
31. Tian, Q., Frierson Jr, H.F., Krystal, G.W., and Moskaluk, C.A. (1999). Activating c-kit gene mutations in human germ cell tumors. Am. J. Pathol. 154, 1643-1647.
32. Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602.
33. Went, P.T., Dirnhofer, S., Bundi, M. et al. (2004). Prevalence of KIT expression in human tumors. J. Clin. Oncol. 22, 4514-4522.
34. Willmore, C., Holden, J.A., Zhou, L., Tripp, S., Wittwer, C.T., and Layfield, L.J. (2004). Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. Am. J. Clin. Pathol. 122, 206-216.
35. Woodman, S.E., Trent, J.C., Stemke-Hale, K. et al. (2009). Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol. Cancer Ther. 8, 2079-2085.
36. Workman, P., Clarke, P.A., Raynaud, F.I., and Van Montfort, R.L. (2010). Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 70, 2146-2157.
37. Wu, J.M., Alvarez, H., Garcia, P., Rojas, P.L., Wong, G., Maitra, A., Antonescu, C., and Montgomery, E.A. (2009). Melanoma hyperpigmentation is strongly associated with KIT alterations. Am. J. Dermatopathol. 31, 619-625.